An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and thymosin beta-4. The panel turned down emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for easier access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how regulators view specialty peptide therapies, which have drawn steady interest from users seeking alternatives to standard drugs. Scientists say peptide treatments could change approaches to resistant infections, though concerns about consistency persist. The committee's endorsement of four peptides paves the way for more expanded prescribing, even as skeptics warn of long-term evidence. Market watchers note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, signals the FDA's cautious stance on particular peptide candidates.